{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:01:15Z","timestamp":1762102875477,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40272-024-00642-w","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T16:02:44Z","timestamp":1719504164000},"page":"475-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Commercial Versus Compounded Preparations in Pediatric Ophthalmology"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7402-4350","authenticated-orcid":false,"given":"Annegret","family":"Dahlmann-Noor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saw Keng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samiya","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanwal","family":"Nischal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Bremond-Gignac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"642_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/pharmaceutics15030840","volume":"15","author":"SH Yuliani","year":"2023","unstructured":"Yuliani SH, Putri DCA, Virginia DM, Gani MR, Riswanto FDO. Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: a review. Pharmaceutics. 2023;15:840.","journal-title":"Pharmaceutics"},{"key":"642_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/ijpp.16.1.0002","volume":"16","author":"JA Giam","year":"2008","unstructured":"Giam JA, Mclachlan AJ. Extemporaneous product use in paediatric patients: a systematic review. IJPP. 2008;16:3\u201310.","journal-title":"IJPP."},{"key":"642_CR3","unstructured":"European Medicines Agency. Paediatric regulation. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/paediatric-medicines-overview\/paediatric-regulation. Accessed 11 Jan 2024."},{"key":"642_CR4","unstructured":"EPTRI. Manifesto on paediatric research. https:\/\/eptri.eu\/research-engagement\/paediatric-manifesto\/. Accessed 11 Jan 2024."},{"key":"642_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/bcp.12268","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor HK, Marriott JF. Formulations for children: problems and solutions. Br J Clin Pharmacol. 2015;79:405\u201318.","journal-title":"Br J Clin Pharmacol"},{"key":"642_CR6","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.15761","volume":"102","author":"J Loughman","year":"2024","unstructured":"Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, et al. Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024;102:e245\u201356.","journal-title":"Acta Ophthalmol"},{"key":"642_CR7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023;141:990\u20139.","journal-title":"JAMA Ophthalmol."},{"key":"642_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SSY Lee","year":"2022","unstructured":"Lee SSY, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial. Clin Exp Ophthalmol. 2022;50:1001\u201312.","journal-title":"Clin Exp Ophthalmol"},{"key":"642_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/bjophthalmol-2021-320318","volume":"107","author":"TR Fricke","year":"2023","unstructured":"Fricke TR, Sankaridurg P, Naduvilath T, Resnikoff S, Tahhan N, He M, et al. Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia. Br J Ophthalmol. 2023;107:1043\u201350.","journal-title":"Br J Ophthalmol"},{"key":"642_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/ICL.0000000000000990","volume":"49","author":"K Richdale","year":"2023","unstructured":"Richdale K, Skidmore KV, Tomiyama ES, Bullimore MA. Compounded 0.01% atropine: what\u2019s in the bottle? Eye Contact Lens. 2023;49:219\u201323.","journal-title":"Eye Contact Lens"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00642-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T06:19:18Z","timestamp":1724307558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00642-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00642-w","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"17 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was not supported by any specific funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Annegret Dahlmann-Noor is\/has been the principal investigator on myopia intervention trials (sponsors: Nevakar, NIHR, Ocumension, DopaVision) and has received speaker\/advisor fees from Santen, Thea, Novartis, CooperVision, SightGlassVision, and Zeiss, for taking part in educational events and\/or advisory boards. Kanwal Nischal is a principal investigator on myopia intervention trials (sponsors: Essilor, Ocumension). Dominique Bremond-Gignac has received speaker\/advisor fees from Alcon, Bausch&Lomb, CooperVision, Essilor, J&J\/Janssen, Hoya, Krys, Santen, Thea, and Zeiss, for taking part in educational events and\/or advisory boards. Jill Bloom, Saw Keng Lee, and Samiya Chowdhury have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ADN conceptualized this article and produced the first draft. JB, SKL, and SC carried out substantial searches of the use of commercial and compounded eye preparations in children in the UK, DBG carried out the same review in France, and KN in the USA. JB, SKL, SC, and KN then wrote the relevant sections. JB, SKL, SC, and KN also wrote sections on the background of compounding preparations and contributed relevant references. All authors critically reviewed and improved earlier and interim drafts of the manuscript. All authors have given approval of the final version of this manuscript, and have agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}